Capricor Therapeutics Investors Have Chance to Lead Class Action Suit
News provided byCapricor Therapeutics, Inc · 1 min read
LOS ANGELES, Sept. 4, 2026 /CourierPR/ -- Capricor Therapeutics, Inc. shareholders who lost money due to alleged securities fraud now have the opportunity to lead a class action lawsuit, according to legal firm Glancy Prongay Wolke & Rotter LLP.
Investors who experienced losses in their Capricor Therapeutics, Inc. investments are urged to act quickly, with the deadline for filing a lead plaintiff motion set for September 28, 2026. According to the lawsuit, between December 17, 2025, and July 26, 2026, the company and its executives made misleading statements and failed to disclose material information about the clinical trial data for Deramiocel, a potential treatment for Duchenne muscular dystrophy.
The lawsuit alleges that the company failed to inform investors about several key issues, including the adoption of a modified statistical analysis plan for Deramiocel, the FDA's lack of prior approval for these changes, and the significant risk that these undisclosed modifications posed to the FDA’s evaluation of Deramiocel’s effectiveness. The firm claims these omissions created a substantial risk to the regulatory approval of the drug and rendered positive statements about the company’s prospects misleading.
The firm notes that shareholders who bought Capricor Therapeutics, Inc. securities during the class period may choose to take no action and remain part of the class as absent members. No class has been certified as of yet.
Glancy Prongay Wolke & Rotter LLP has a long track record of success in securities litigation. The firm was recognized as one of Law360’s Securities Groups of the Year in 2025 and ranked second in total investor recoveries by Institutional Shareholder Services Securities Class Action Services. The firm has handled cases involving corporate misconduct across various industries and has been widely covered by major publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, and Forbes.